Radiomic Phenotypes for Improving Early Prediction of Survival in Stage III Non-Small Cell Lung Cancer Adenocarcinoma after Chemoradiation
Authors:
- José Marcio LunaJLJosé Marcio Luna
- Andrew R. BarskyABAndrew R. Barsky
- Russell T. ShinoharaRSRussell T. Shinohara
- Leonid RoshkovanLRLeonid Roshkovan
- Michelle HershmanMHMichelle Hershman
- Alexandra D. DreyfussADAlexandra D. Dreyfuss
- Hannah HorngHHHannah Horng
- Carolyn LouCLCarolyn Lou
- Peter B. NoëlPNPeter B. Noël
- Keith A. CengelKCKeith A. Cengel
- Sharyn KatzSKSharyn Katz
- Eric S. DiffenderferEDEric S. Diffenderfer
Open Access
Abstract
We evaluate radiomic phenotypes derived from CT scans as early predictors of overall survival (OS) after chemoradiation in stage III primary lung adenocarcinoma. We retrospectively analyzed 110 thoracic CT scans acquired between April 2012−October 2018. Patients received a median radiation dose of 66.6 Gy at 1.8 Gy/fraction delivered with proton (55.5%) and photon (44.5%) beam treatment, as well as concurrent chemotherapy (89%) with carboplatin-based (55.5%) and cisplatin-based (36.4%) doublets. A total of 56 death events were recorded. Using manual tumor segmentations, 107 radiomic features were extracted. Feature harmonization using ComBat was performed to mitigate image heterogeneity due to the presence or lack of intravenous contrast material and variability in CT scanner vendors. A binary radiomic phenotype to predict OS was derived through the unsupervised hierarchical clustering of the first principal components explaining 85% of the variance of the radiomic features. C-scores and likelihood ratio tests (LRT) were used to compare the performance of a baseline Cox model based on ECOG status and age, with a model integrating the radiomic phenotype with such clinical predictors. The model integrating the radiomic phenotype (C-score = 0.69, 95% CI = (0.62, 0.77)) significantly improved () upon the baseline model (C-score = 0.65, CI = (0.57, 0.73)). Our results suggest that harmonized radiomic phenotypes can significantly improve OS prediction in stage III NSCLC after chemoradiation.
Keywords
This publication has 55 references indexed in Scilit:
- Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 studyThe Lancet Oncology, 2015
- Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approachNature Communications, 2014
- Predicting outcomes in radiation oncology—multifactorial decision support systemsNature Reviews Clinical Oncology, 2012
- Histologic coagulative tumour necrosis as a prognostic indicator of aggressiveness in renal, lung, thyroid and colorectal carcinomas: A brief reviewOncology Letters, 2011
- Tumor Necrosis as a Prognostic Factor for Stage IA Non-Small Cell Lung CancerThe Annals of Thoracic Surgery, 2011
- International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung AdenocarcinomaJournal of Thoracic Oncology, 2011
- Phase III Study of Cisplatin, Etoposide, and Concurrent Chest Radiation With or Without Consolidation Docetaxel in Patients With Inoperable Stage III Non–Small-Cell Lung Cancer: The Hoosier Oncology Group and U.S. OncologyJournal of Clinical Oncology, 2008
- Adjusting batch effects in microarray expression data using empirical Bayes methodsBiostatistics, 2006
- Combined Chemoradiotherapy Regimens of Paclitaxel and Carboplatin for Locally Advanced Non–Small-Cell Lung Cancer: A Randomized Phase II Locally Advanced Multi-Modality ProtocolJournal of Clinical Oncology, 2005
- Consolidation Docetaxel After Concurrent Chemoradiotherapy in Stage IIIB Non–Small-Cell Lung Cancer: Phase II Southwest Oncology Group Study S9504Journal of Clinical Oncology, 2003